Skip to main content

Secukinumab Dosage

Medically reviewed by Drugs.com. Last updated on Oct 7, 2024.

Applies to the following strengths: 150 mg/mL; 75 mg/0.5 mL; 300 mg/2 mL; 25 mg/mL

Usual Adult Dose for Plaque Psoriasis

300 mg subcutaneously at Weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter


Comments:

Use: For the treatment of moderate to severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy

Usual Adult Dose for Psoriatic Arthritis

IV DOSAGE:


SUBCUTANEOUS DOSAGE:
For Psoriatic Arthritis Patients With Coexistent Moderate to Severe Plaque Psoriasis: 300 mg subcutaneously at Weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter

For Other Psoriatic Arthritis Patients:

Comments:

Use: For the treatment of active psoriatic arthritis

Usual Adult Dose for Ankylosing Spondylitis

IV DOSAGE:


SUBCUTANEOUS DOSAGE:

Comments:

Use: For the treatment of patients with active ankylosing spondylitis

Usual Adult Dose for Non-Radiographic Axial Spondyloarthritis

IV DOSAGE:


SUBCUTANEOUS DOSAGE:

Comments:

Use: For the treatment of patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation

Usual Adult Dose for Hidradenitis Suppurativa

300 mg subcutaneously at Weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter


Comments:

Use: For the treatment of patients with moderate to severe hidradenitis suppurativa

Usual Pediatric Dose for Plaque Psoriasis

6 years and older:


Use: For the treatment of moderate to severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy

Usual Pediatric Dose for Juvenile Psoriatic Arthritis

2 years and older:


Comments:

Use: For the treatment of active juvenile psoriatic arthritis

Usual Pediatric Dose for Enthesitis-Related Arthritis

4 years and older:


Use: For the treatment of active enthesitis-related arthritis

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:


IV administration: Safety and efficacy have not been established in patients younger than 18 years.

Subcutaneous administration:

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

IV Infusion:
Subcutaneous Injection:

Storage requirements:

Reconstitution/preparation techniques:

IV compatibility:

General:

Monitoring:

Patient advice:

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.